TY - JOUR
T1 - Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa
AU - Lavoue, Vincent
AU - Huchon, Cyrille
AU - Akladios, Cherif
AU - Alfonsi, Pascal
AU - Bakrin, Naoual
AU - Ballester, Marcos
AU - Bendifallah, Sofiane
AU - Bolze, Pierre Adrien
AU - Bonnet, Fabrice
AU - Bourgin, Charlotte
AU - Chabbert-Buffet, Nathalie
AU - Collinet, Pierre
AU - Courbiere, Blandine
AU - De la Motte Rouge, Thibault
AU - Devouassoux-Shisheboran, Mojgan
AU - Falandry, Claire
AU - Ferron, Gwenal
AU - Fournier, Laure
AU - Gladieff, Laurence
AU - Golfier, François
AU - Gouy, Sébastien
AU - Guyon, Frédérique
AU - Lambaudie, Eric
AU - Leary, Alexandra
AU - Lecuru, Fabrice
AU - Lefrere-Belda, Marie Aude
AU - Leblanc, Eric
AU - Lemoine, Adrien
AU - Narducci, Fabrice
AU - Ouldamer, Lobna
AU - Pautier, Patricia
AU - Planchamp, François
AU - Pouget, Nicolas
AU - Ray-Coquard, Isabelle
AU - Rousset-Jablonski, Christine
AU - Senechal-Davin, Claire
AU - Touboul, Cyril
AU - Thomassin-Naggara, Isabelle
AU - Uzan, Catherine
AU - You, Benoit
AU - Daraï, Emile
N1 - Publisher Copyright:
© 2019 Société Française du Cancer
PY - 2019/4/1
Y1 - 2019/4/1
N2 - Faced to an undetermined ovarian mass on ultrasound, an MRI is recommended and the ROMA score (combining CA125 and HE4) can be proposed (grade A). In case of suspected early stage ovarian or fallopian tube cancer, omentectomy (at least infracolonic), appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C) and pelvic and para-aortic lymphadenectomy are recommended (grade B) for all histological types, except for the expansive mucinous subtype where lymphadenectomy may be omitted (grade C). Minimally invasive surgery is recommended for early stage ovarian cancer, if there is no risk of tumor rupture (grade B). Adjuvant chemotherapy with carboplatin and paclitaxel is recommended for all high-grade ovarian or Fallopian tube cancers, stage FIGO I-IIA (grade A). In case of ovarian, Fallopian tube or primitive peritoneal cancer of FIGO III-IV stages, thoraco-abdomino-pelvic CT scan with injection (grade B) is recommended. Laparoscopic exploration for multiple biopsies (grade A) and to evaluate carcinomatosis score (at least using the Fagotti score) (grade C) are recommended to estimate the possibility of a complete surgery (i.e. no macroscopic residue). Complete medial laparotomy surgery is recommended for advanced cancers (grade B). It is recommended in advanced cancers to perform para-aortic and pelvic lymphadenectomy in case of clinical or radiological suspicion of metastatic lymph node (grade B). In the absence of clinical or radiological lymphadenopathy and in case of complete peritoneal surgery during an initial surgery for advanced cancer, it is possible not to perform a lymphadenectomy because it does not modify the medical treatment and the overall survival (grade B). Primary surgery is recommended when no tumor residue is possible (grade B). After a complete first surgery, it is recommended to deliver 6 cycles of intravenous (grade A) or to propose intraperitoneal (grade B) chemotherapy, to be discussed with patient, according to the benefit/risk ratio. After a complete interval surgery for a FIGO III stage, the hyperthermic intra peritoneal chemotherapy (HIPEC) can be proposed in the same conditions of the OV-HIPEC trial (grade B). In case of tumor residue after surgery or FIGO stage IV, chemotherapy associated with bevacizumab is recommended (grade A).
AB - Faced to an undetermined ovarian mass on ultrasound, an MRI is recommended and the ROMA score (combining CA125 and HE4) can be proposed (grade A). In case of suspected early stage ovarian or fallopian tube cancer, omentectomy (at least infracolonic), appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C) and pelvic and para-aortic lymphadenectomy are recommended (grade B) for all histological types, except for the expansive mucinous subtype where lymphadenectomy may be omitted (grade C). Minimally invasive surgery is recommended for early stage ovarian cancer, if there is no risk of tumor rupture (grade B). Adjuvant chemotherapy with carboplatin and paclitaxel is recommended for all high-grade ovarian or Fallopian tube cancers, stage FIGO I-IIA (grade A). In case of ovarian, Fallopian tube or primitive peritoneal cancer of FIGO III-IV stages, thoraco-abdomino-pelvic CT scan with injection (grade B) is recommended. Laparoscopic exploration for multiple biopsies (grade A) and to evaluate carcinomatosis score (at least using the Fagotti score) (grade C) are recommended to estimate the possibility of a complete surgery (i.e. no macroscopic residue). Complete medial laparotomy surgery is recommended for advanced cancers (grade B). It is recommended in advanced cancers to perform para-aortic and pelvic lymphadenectomy in case of clinical or radiological suspicion of metastatic lymph node (grade B). In the absence of clinical or radiological lymphadenopathy and in case of complete peritoneal surgery during an initial surgery for advanced cancer, it is possible not to perform a lymphadenectomy because it does not modify the medical treatment and the overall survival (grade B). Primary surgery is recommended when no tumor residue is possible (grade B). After a complete first surgery, it is recommended to deliver 6 cycles of intravenous (grade A) or to propose intraperitoneal (grade B) chemotherapy, to be discussed with patient, according to the benefit/risk ratio. After a complete interval surgery for a FIGO III stage, the hyperthermic intra peritoneal chemotherapy (HIPEC) can be proposed in the same conditions of the OV-HIPEC trial (grade B). In case of tumor residue after surgery or FIGO stage IV, chemotherapy associated with bevacizumab is recommended (grade A).
KW - Chemotherapy
KW - Fallopian tube cancer
KW - Guidelines
KW - Ovarian cancer
KW - Peritoneal cancer
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85062352909&partnerID=8YFLogxK
U2 - 10.1016/j.bulcan.2019.01.014
DO - 10.1016/j.bulcan.2019.01.014
M3 - Review article
C2 - 30850152
AN - SCOPUS:85062352909
SN - 0007-4551
VL - 106
SP - 354
EP - 370
JO - Bulletin du Cancer
JF - Bulletin du Cancer
IS - 4
ER -